Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Twist Bioscience
Twist Bioscience
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Pharmaceutical
Twist Bioscience puts antibody optimisation potential to use
Partnership to apply antibody optimisation platform to the targeting arm of a bispecific antibody
Manufacturing
Twist Bioscience and LakePharma share resources for antibody platform
Twist will provide its antibody discovery platform, LakePharma will provide development services
Manufacturing
Automated microfluidics for gene editing is in the works
Oxford Genetics has announced a partnership to optimise the way laboratories deliver gene editing to cells and interrogate the resultant products
Research & Development
Leaders of transformation
Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development
Subscribe now